Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04543617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Study acronym: SKYSCRAPER-07
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 54 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial completed Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026 · Study sites: 167 to 166v54 Show 2 more changesShow less
    • Primary completion date changed from estimate of Mar 31, 2027 to Jul 22, 2026
    • Study sites: 167 to 166
  2. Re-verified, no change to tracked fieldsv53
  3. Study sites: 165 to 167v52
  4. Study sites revised (165)v51 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 166 to 165v50
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (166)v49 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 163 to 166v48
  3. Study sites: 179 to 163v47
  4. Study sites: 180 to 179v46
  5. Re-verified, no change to tracked fieldsv45
  6. Study sites: 181 to 180v44
  7. Re-verified, no change to tracked fieldsv43
  8. Study sites: 185 to 181v42
  9. Study sites: 190 to 185v41
  10. Study sites: 193 to 190v40
  11. Primary completion date: Dec 19, 2024 to Mar 31, 2027 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 750 to confirmed 760 · Study sites: 231 to 193 · 1 morev39 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 750 to confirmed 760
    • Study sites: 231 to 193
    • Completion date: Jun 27, 2025 to Mar 31, 2027
  12. Site details revised at 29 of 231 sitesv38
  13. Site details revised at 27 of 231 sitesv37
  14. Study sites revised (231)v36 See this version in full on ClinicalTrials.gov ↗
  15. Site details revised at 9 of 231 sitesv35
  16. Site details revised at 12 of 231 sitesv34
  17. Site details revised at 10 of 231 sitesv33
  18. Site details revised at 14 of 231 sitesv32
  19. Study sites revised (231)v31 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (231)v30 See this version in full on ClinicalTrials.gov ↗
  21. Completion date: Dec 26, 2025 to Jun 27, 2025 Study sites revised (231)v29 Show 1 more changeShow less
    • Study sites revised (231)

    See this version in full on ClinicalTrials.gov ↗

  22. Site details revised at 16 of 231 sitesv28
  23. Study sites: 230 to 231v27
  24. Study sites: 229 to 230v26
  25. Study sites: 228 to 229v25
  26. Study sites: 224 to 228v24
  27. Study sites: 223 to 224v23
  28. Site details revised at 14 of 223 sitesv22
  29. Study sites: 220 to 223v21
  30. Site details revised at 8 of 220 sitesv20
  31. Study sites: 218 to 220v19
  32. Study sites: 208 to 218v18
  33. Study sites: 206 to 208v17
  34. Study sites: 220 to 206v16
  35. Study sites: 218 to 220v15
  36. Study sites: 215 to 218 Eligibility criteria expanded, about 2 wordsv14 Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  37. Re-verified, no change to tracked fieldsv13
  38. Study sites: 214 to 215v12
  39. Site details revised at 13 of 214 sitesv11
  40. Study sites: 213 to 214v10
  41. Study sites: 211 to 213v9
  42. Study sites: 213 to 211v8
  43. Study sites: 212 to 213v7
  44. Study sites revised (212)v6 See this version in full on ClinicalTrials.gov ↗
  45. Study sites: 213 to 212v5
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
Trial Details
NCT Number NCT04543617
Lead Sponsor Hoffmann-La Roche
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 760 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov